Avaliação do Risco de Sarcopenia em Pessoas Vivendo com a Síndrome da Imunodeficiência Humana

Víctor Almir Leão Fortunato; Phablo Guilherme de Assis Alves; Jeremias Estevam Lopes; Maria Clara de Castro Coqueiro da Silva; João Victor Machado Cristo; Juliana Aires Matos; Rosana Maria Feio Libonati

doi:10.36489/saudecoletiva.2015v15i95p15496-15507

Autores

Víctor Almir Leão Fortunato Bacharelado em Medicina - Universidade Federal do Pará. https://orcid.org/0000-0002-3597-7634
Phablo Guilherme de Assis Alves Bacharelado em Medicina - Universidade Federal do Pará. https://orcid.org/0009-0005-9859-2271
Jeremias Estevam Lopes Graduando em Medicina - Universidade Federal do Pará. https://orcid.org/0009-0003-8283-8500
Maria Clara de Castro Coqueiro da Silva Graduanda em Medicina - Universidade Federal do Pará. https://orcid.org/0000-0002-0532-5045
João Victor Machado Cristo Graduando em Medicina - Universidade Federal do Pará. https://orcid.org/0000-0001-7784-8892
Juliana Aires Matos Graduanda em Medicina - Universidade Federal do Pará. https://orcid.org/0009-0003-0123-5602
Rosana Maria Feio Libonati Doutora em Ciências Biológicas - Universidade Federal do Pará. https://orcid.org/0000-0002-1425-7806

DOI:

https://doi.org/10.36489/saudecoletiva.2015v15i95p15496-15507

Palavras-chave:

HIV, Lipodistrofia, Sarcopenia, Risco, Síndrome da Imunodeficiência Adquirida

Resumo

Objetivo: Avaliar o risco de sarcopenia em pacientes com lipodistrofia associada ao vírus da imunodeficiência humana em tratamento antirretroviral, atendidos em ambulatório de Belém do Pará. Método: Estudo observacional transversal, realizado com 66 pacientes entre maio e junho de 2023. Foram utilizados os protocolos SARC-F e SARC-Calf, com cálculos de intervalos de confiança de 95%, odds ratio, teste t de Student e índice Kappa para verificar a concordância entre as escalas. Resultado: A amostra foi masculina (54,5%) e a maioria na faixa etária de 40 a 59 anos (56,1%). Lipodistrofia mista prevaleceu (83,3%), e o risco de sarcopenia foi identificado em 34,8% dos casos, sendo mais frequente no sexo feminino, com chance 6,54 vezes maior (p=0,002) e tendência em idades avançadas (p=0,051). Conclusão: O sexo feminino e a idade avançada constituem fatores de risco independentes. Os achados reforçam a necessidade do rastreio de sarcopenia para aprimorar programas de saúde pública.

Referências

Mu W, Patankar V, Kitchen S, Zhen A. Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection. Viruses. 2024 Jan 31;16(2):219–9. DOI: https://doi.org/10.3390/v16020219

Guimarães NS, Raposo MA, Greco D, Tupinambás U, Premaor MO. People Living With HIV, Lean Mass, and Sarcopenia: A Systematic Review and Meta-Analysis. J Clin Densitom. 2022 Jan-Mar;25(1):113-123. DOI: https://doi.org/10.1016/j.jocd.2021.03.004

Sanchez-Tocino ML, Secundino Cigarrán, Ureña P, González-Casaus ML, Mas-Fontao S, Gracia-Iguacel C, et al. Definition and evolution of the concept of sarcopenia. Nefrología (English Edition). 2024 May 1;44(3):323–30. DOI: https://doi.org/10.1016/j.nefroe.2023.08.007

Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013 Aug;14(8):531-2. DOI: https://doi.org/10.1016/j.jamda.2013.05.018

Vieira LC, Ximenez JA, Spexoto MCB. Agreement analysis and associated factors of SARC-F and SARC-CALF in screening of risk sarcopenia in people living with human immunodeficiency virus. Clinics. 2025 Jan 3;80:100565. DOI: https://doi.org/10.1016/j.clinsp.2024.100565

Bahat G, Erdoğan T, İlhan B. SARC-F and other screening tests for sarcopenia. Curr Opin Clin Nutr Metab Care. 2022 Jan 1;25(1):37-42. DOI: https://doi.org/10.1097/MCO.0000000000000801

Barbosa-Silva TG, et al. Enhancing SARC-F: Improving Sarcopenia Screening in the Clinical Practice. J Am Med Dir Assoc. 2016 Dec 1;17(12):1136-1141. DOI: https://doi.org/10.1016/j.jamda.2016.08.004

Krzymińska-Siemaszko R, et al. Comparison of Diagnostic Performance of SARC-F and Its Two Modified Versions (SARC-CalF and SARC-F+EBM) in Community-Dwelling Older Adults from Poland. Clin Interv Aging. 2020 Apr 28;15:583-594. DOI: https://doi.org/10.2147/CIA.S250508

Grech V, Eldawlatly AA. STROBE, CONSORT, PRISMA, MOOSE, STARD, SPIRIT, and other guidelines – Overview and application. Saudi J Anaesth. 2024 Jan-Mar;18(1):137-141. DOI: https://doi.org/10.4103/sja.sja_545_23

Echeverría P, et al. High Prevalence of Sarcopenia in HIV-Infected Individuals. Biomed Res Int. 2018 Jul 12;2018:5074923. DOI: https://doi.org/10.1155/2018/5074923

Portney LG, Watkins MP. Foundations of Clinical Research: Applications to Practice. 2nd ed. Prentice Hall Health; 2000.

Souza DE, Carmo CN, Welch JR. Temporal analysis and contextual factors associated with HIV/AIDS in Brazil from 2000 to 2019. Rev Saude Publica. 2023 Nov 17;57:91. DOI: https://doi.org/10.11606/s1518-8787.2023057005508

Hawkins KL, et al. Abdominal obesity, sarcopenia, and osteoporosis associated with frailty in men living with and without HIV. AIDS. 2018 Jun 19;32(10):1257-1266. DOI: https://doi.org/10.1097/QAD.0000000000001829

Li X, et al. Inflammation and aging: signaling pathways and intervention therapies. Inflamm Aging. 2023 Jun 8;8(1). DOI: https://doi.org/10.1038/s41392-023-01502-8

Konishi K, et al. Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition. Medicine. 2022 Oct 21;101(42):e31349–9. DOI: https://doi.org/10.1097/MD.0000000000031349

Conde-Higuera P, et al. Sarcopenia in people living with HIV. Aids Reviews. 2022 Nov 22;24(4). DOI: https://doi.org/10.24875/AIDSRev.22000010

Wasserman P, et al. High prevalence of low skeletal muscle mass associated with male gender in midlife and older HIV-infected persons despite CD4 cell reconstitution and viral suppression. J Int Assoc Provid AIDS Care. 2014 Mar-Apr;13(2):145-52. DOI: https://doi.org/10.1177/2325957413495919

Degli Antoni A, et al. A Reduction Grade of Lipodystrophy and Limited Side Effects after HAART Regimen with Raltegravir, Lamivudine, Darunavir and Ritonavir in HIV-1 Infected Patient after Six Years of Antiretroviral Therapy. West Indian Med J. 2015 Jun;64(3):291-3. DOI: https://doi.org/10.7727/wimj.2014.066

Kajogoo VD, et al. HIV Protease Inhibitors and Insulin Sensitivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2021 Nov 1;12:635089. DOI: https://doi.org/10.3389/fphar.2021.635089

Bourgeois C, Gorwood J, Olivo A, Le Pelletier L, Capeau J, Lambotte O, et al. Contribution of Adipose Tissue to the Chronic Immune Activation and Inflammation Associated With HIV Infection and Its Treatment. Frontiers in Immunology. 2021 Jun 18;12. DOI: https://doi.org/10.3389/fimmu.2021.670566

Ramirez CE, et al. Adipose Tissue Dysfunction and Energy Balance Paradigms in People Living With HIV. Endocr Rev. 2023 Aug 9;45(2):190–209. DOI: https://doi.org/10.1210/endrev/bnad028

Pontes-Pereira PS, et al. Prevalência de doenças crônicas não transmissíveis em pessoas vivendo com HIV. Acta paul enferm. 2023;36:eAPE01132. DOI: https://doi.org/10.37689/acta-ape/2023AO01132

Zatterale F, et al. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front Physiol. 2020 Jan 29;10:1607. DOI: https://doi.org/10.3389/fphys.2019.01607

Lombardi F, Belmonti S, Sanfilippo A, Borghetti A, Iannone V, Salvo PF, et al. Factors associated with oxidative stress in virologically suppressed people living with HIV on long-term antiretroviral therapy. AIDS Research and Therapy. 2024 Dec 30;21(1). DOI: https://doi.org/10.1186/s12981-024-00694-5

Santos LS, et al. Accuracy and Applicability of the SARC-F and SARC-CalF Questionnaire in the Screening of Sarcopenia in Hospitalized Elderly Patients. Aging Med Healthc. 2023;14(4):201-208. DOI: https://doi.org/10.33879/AMH.144.2022.05047